In vitro activity of clindamycin, doxycycline, and trimethoprim/sulfamethoxazole against clinical isolates of β-hemolytic Streptococcus spp. via BD Phoenix and broth microdilution

Christian Cho; Ryan K Shields; Ellen G Kline; Thomas L Walsh; Chelsea E Jones; Karen Kasarda; Kelly Stefano; Matthew A Moffa; Derek N Bremmer

doi:10.1017/ash.2023.515

In vitro activity of clindamycin, doxycycline, and trimethoprim/sulfamethoxazole against clinical isolates of β-hemolytic Streptococcus spp. via BD Phoenix and broth microdilution

Antimicrob Steward Healthc Epidemiol. 2023 Dec 15;3(1):e238. doi: 10.1017/ash.2023.515. eCollection 2023.

Authors

Christian Cho¹, Ryan K Shields^{2

3

4}, Ellen G Kline³, Thomas L Walsh⁵, Chelsea E Jones³, Karen Kasarda⁶, Kelly Stefano⁶, Matthew A Moffa⁵, Derek N Bremmer¹

Affiliations

¹ Department of Pharmacy, Allegheny Health Network, Pittsburgh, PA, USA.
² Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
³ Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
⁴ XDR Pathogens Laboratory, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
⁵ Division of Infectious Diseases, Allegheny Health Network, Pittsburgh, PA, USA.
⁶ Department of Pathology and Laboratory Medicine, Allegheny Health Network, Pittsburgh, PA, USA.

Abstract

We tested 85 isolates of β-hemolytic Streptococcus spp. against trimethoprim/sulfamethoxazole (TMP/SMX), clindamycin, and doxycycline by broth microdilution (BMD) and BD Phoenix. Susceptibility rates via BMD for TMP/SMX, clindamycin, and doxycycline were 100%, 85.5%, and 56.6%, respectively. TMP/SMX is a potential monotherapy agent for β-hemolytic Streptococcus skin and soft tissue infections.